Completed PHASE2 INTERVENTIONAL NCT00323505

A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma

Sponsor: Royal Marsden NHS Foundation Trust

Interventions Interferon-alpha2a Pegylated Interferon

Updated 4 times since 2017 Last updated: May 8, 2006 Started: Mar 31, 2001 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Multiple Myeloma and is currently completed. Royal Marsden NHS Foundation Trust leads this study, which shows 4 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2017 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Mar 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Royal Marsden NHS Foundation Trust

Data source: Royal Marsden NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sutton, United Kingdom